Thomas DiRaimondo, Ph.D., is a distinguished scientist and the Chief Scientific Officer at JANUX THERAPEUTICS INC., a biopharmaceutical company focused on developing novel therapies for cancer and other serious diseases. Dr. DiRaimondo earned his Ph.D. in Chemistry from the University of California, Berkeley, where his research concentrated on the synthesis and study of complex organic molecules. His academic journey laid a strong foundation for his subsequent career in the pharmaceutical industry, where he has made significant contributions to drug discovery and development. Before joining JANUX THERAPEUTICS INC., Dr. DiRaimondo held several key positions at leading biopharmaceutical companies, including Amgen and Genentech. At Amgen, he led a team of researchers in the discovery of novel small molecule inhibitors targeting cancer pathways, resulting in several promising drug candidates entering clinical trials. His time at Genentech was marked by his role in advancing the development of biologics, where he spearheaded projects that enhanced the company's pipeline of therapeutic antibodies. These experiences have equipped him with a deep understanding of both small molecule and biologic drug development. As Chief Scientific Officer at JANUX THERAPEUTICS INC., Dr. DiRaimondo plays a pivotal role in steering the company's scientific strategy and overseeing its research and development efforts. His leadership has been instrumental in advancing JANUX's innovative T-cell engager platform, which aims to harness the power of the immune system to treat cancer more effectively. Under his guidance, the company has made significant strides in preclinical and clinical development, positioning JANUX at the forefront of immuno-oncology. Dr. DiRaimondo's vision and expertise continue to drive the company's mission to deliver transformative therapies to patients in need.